What were the key financial results reported for the second fiscal quarter ending March 31, 2021?

The 8-K filing does not provide specific figures for revenue or EPS in the text itself, but it states that BDX issued a press release on May 6, 2021, announcing these results. Investors should refer to Exhibit 99.1 (the press release) for detailed financial performance data, including GAAP and non-GAAP measures like currency-neutral revenue growth and adjusted EPS.

Why did BDX present non-GAAP financial measures?

BDX presented non-GAAP measures, such as currency-neutral revenue growth and adjusted EPS, to provide investors with a clearer understanding of the company's underlying operational performance. These adjustments exclude items that management believes do not reflect ordinary operations or affect period-to-period comparability, such as currency fluctuations, purchase accounting adjustments, integration costs, and others. Management uses these measures for operational decision-making and believes they facilitate comparisons.

What is the strategic significance of spinning off the Diabetes Care business?

The spin-off of the Diabetes Care business aims to create a separate, publicly traded entity. This strategic move is intended to allow both BDX and the new Diabetes Care company to focus more effectively on their respective strategic priorities, potentially unlocking greater value and enabling more tailored capital allocation and growth strategies for each business.

When is the Diabetes Care business spin-off expected to be completed?

The spin-off is expected to be completed in the first half of calendar year 2022. This timeline is subject to customary conditions, including final approval from BDX's Board of Directors and the effectiveness of a registration statement to be filed with the SEC.

BDX 8-K: Earnings & Results & Regulation FD

Summary

Becton, Dickinson and Company (BDX) filed a Form 8-K on May 6, 2021, primarily to disclose its second fiscal quarter financial results and a significant strategic announcement regarding its Diabetes Care business. The company reported its financial results for the quarter ending March 31, 2021, utilizing both GAAP and non-GAAP measures, including currency-neutral revenue growth and adjusted earnings per share (EPS). The press release accompanying these results, furnished as Exhibit 99.1, provides details on adjustments made to GAAP figures to offer a clearer view of underlying operational performance and comparability. More notably, BDX announced its intention to spin off its Diabetes Care business into a separate, publicly traded company. This transaction is planned as a tax-free event for U.S. federal income tax purposes and is expected to be completed in the first half of calendar year 2022, pending customary conditions and board approval. This strategic move signals a significant shift in BD's portfolio and future focus.

Key Highlights

1BDX announced its Q2 fiscal year 2021 financial results on May 6, 2021.
2The company provided financial metrics using both GAAP and non-GAAP measures, including currency-neutral revenue growth and adjusted EPS.
3BDX intends to spin off its Diabetes Care business as a separate publicly traded company.
4The proposed spin-off is expected to be a tax-free transaction for U.S. federal income tax purposes.
5The completion of the spin-off is anticipated in the first half of calendar year 2022.
6The spin-off is subject to customary conditions, including final Board of Directors approval and SEC filings.
7The press releases detailing the financial results and the spin-off announcement are furnished as exhibits.

BECTON DICKINSON & CO 8-K Report, Financial Results (May 6, 2021)

Summary

Key Highlights

Frequently Asked Questions